Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 21, 2022 at 07:18 am EDT
Share
Shenzhen New Industries Biomedical Engineering Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 742.83 million compared to CNY 532.37 million a year ago. Revenue was CNY 742.83 million compared to CNY 532.37 million a year ago. Net income was CNY 308.48 million compared to CNY 168.14 million a year ago. Basic earnings per share from continuing operations was CNY 0.3926 compared to CNY 0.2146 a year ago. Diluted earnings per share from continuing operations was CNY 0.3921 compared to CNY 0.2146 a year ago.
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. 
